Targeting pediatric solid tumors in the new era of RNA therapeutics
4
item.page.dc.date.issued
2024-08-01
item.page.dc.type
item.page.dc.identifier.issn
10408428
item.page.dc.identifier.eissn
18790461
item.page.dc.identifier.doi
item.page.dc.identifier.scopus
2-s2.0-85195181505
item.page.oaire.citation.title
Critical Reviews in Oncology/Hematology
item.page.oaire.citation.volume
200
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Critical Reviews in Oncology/Hematology Vol.200 (2024)
punsarn.item.page.citation
Chaiyawat P., Sangkhathat S., Chiangjong W., Wongtrakoongate P., Hongeng S., Pruksakorn D., Chutipongtanate S. Targeting pediatric solid tumors in the new era of RNA therapeutics. Critical Reviews in Oncology/Hematology Vol.200 (2024). doi:10.1016/j.critrevonc.2024.104406 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/98705
item.page.dc.title
Targeting pediatric solid tumors in the new era of RNA therapeutics
item.page.dc.contributor.author
item.page.dc.contributor.correspondence
item.page.dc.contributor.other
item.page.dc.description.abstract
Despite substantial progress in pediatric cancer treatment, poor prognosis remained for patients with recurrent or metastatic disease, given the limitations of approved targeted treatments and immunotherapies. RNA therapeutics offer significant potential for addressing a broad spectrum of diseases, including cancer. Advances in manufacturing and delivery systems are paving the way for the rapid development of therapeutic RNAs for clinical applications. This review summarizes therapeutic RNA classifications and the mechanisms of action, highlighting their potential in manipulating major cancer-related pathways and biological effects. We also focus on the pre-clinical investigation of RNA molecules with efficient delivery systems for their therapeutic potential targeting pediatric solid tumors.
